Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | PREP | P48147 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15624132 | 0.95 | HPGD (0.49) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15624147 | 0.95 | HPGD (0.49) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17248133 | 0.93 | HPGD (0.51) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL173435 | 0.89 | USP2 (0.49) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11913651 | 0.88 | USP2 (0.51) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15624094 | 0.88 | USP2 (0.51) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| Acetic Acid SCHEMBL27630753 | 0.85 | USP2 (0.45) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL833441 | 0.84 | HPGD (0.47) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL222920 | 0.83 | PREP (0.53) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2596349 | 0.80 | PTPN2 (0.48) | USP2SMN1; SMN2MEN1KMT2APREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116888-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | NOVARTIS AG (CH) | 2026-04-30 | — | — | US | disclosed |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250179093-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025064542-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-118647610-A | Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-111051298-B | 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof | 诺华股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-3459944-B1 | AZEPANYL-DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME WITH ANTIPARASITIC ACTIVITY | MERCK PATENT GMBH (DE) | 2021-01-06 | — | — | EP | disclosed |
| CN-111533734-A | Azepanyl derivatives having antiparasitic activity and pharmaceutical compositions containing them | 默克专利股份有限公司 | 2020-08-14 | — | — | CN | disclosed |
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-0856002-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1998-08-05 | — | — | EP | disclosed |
| WO-1997009328-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179093-A1 | KRAS MODULATORS | KRAS, NRAS, HRAS | HPGD 2680/4885USP2 1013/4885SMN1; SMN2 3622/4885 |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | HPGD 1094/4885USP2 2827/4885SMN1; SMN2 2585/4885 |
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | HPGD 471/4885USP2 2159/4885SMN1; SMN2 4669/4885 |
| US-20260116888-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK4, CCNC, CDK6 | HPGD 2637/4885USP2 2411/4885SMN1; SMN2 3613/4885 |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | HPGD 1094/4885USP2 2827/4885SMN1; SMN2 2585/4885 |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | HPGD 2903/4885USP2 3777/4885SMN1; SMN2 2906/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | HPGD 1200/4885USP2 2730/4885SMN1; SMN2 4769/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | HPGD 471/4885USP2 2159/4885SMN1; SMN2 4669/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | HPGD 471/4885USP2 2159/4885SMN1; SMN2 4669/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | HPGD 471/4885USP2 2159/4885SMN1; SMN2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.